405 related articles for article (PubMed ID: 19589810)
1. Pharmacodynamics of moxifloxacin against a high inoculum of Escherichia coli in an in vitro infection model.
Singh R; Ledesma KR; Chang KT; Hou JG; Prince RA; Tam VH
J Antimicrob Chemother; 2009 Sep; 64(3):556-62. PubMed ID: 19589810
[TBL] [Abstract][Full Text] [Related]
2. In vitro pharmacodynamics of moxifloxacin versus levofloxacin against 4 strains of Streptococcus pneumoniae: 1 wild type, 2 first-step parC mutants, and 1 pump mutant.
Schafer J; Hovde LB; Simonson D; Rotschafer JC
Diagn Microbiol Infect Dis; 2008 Feb; 60(2):155-61. PubMed ID: 17910998
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamics of moxifloxacin and levofloxacin against Streptococcus pneumoniae, Staphylococcus aureus, Klebsiella pneumoniae and Escherichia coli: simulation of human plasma concentrations after intravenous dosage in an in vitro kinetic model.
Odenholt I; Cars O
J Antimicrob Chemother; 2006 Nov; 58(5):960-5. PubMed ID: 16936293
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of bacterial kill when modelling the bronchopulmonary pharmacokinetic profile of moxifloxacin and levofloxacin against parC-containing isolates of Streptococcus pneumoniae.
Deryke CA; Du X; Nicolau DP
J Antimicrob Chemother; 2006 Sep; 58(3):601-9. PubMed ID: 16857688
[TBL] [Abstract][Full Text] [Related]
5. Emergence of high-level fluoroquinolone resistance in emm6 Streptococcus pyogenes and in vitro resistance selection with ciprofloxacin, levofloxacin and moxifloxacin.
Malhotra-Kumar S; Van Heirstraeten L; Lammens C; Chapelle S; Goossens H
J Antimicrob Chemother; 2009 May; 63(5):886-94. PubMed ID: 19279051
[TBL] [Abstract][Full Text] [Related]
6. Molecular characterization of moxifloxacin resistance from Canadian Clostridium difficile clinical isolates.
Walkty A; Boyd DA; Gravel D; Hutchinson J; McGeer A; Moore D; Simor A; Suh K; Taylor G; Miller M; Mulvey MR;
Diagn Microbiol Infect Dis; 2010 Apr; 66(4):419-24. PubMed ID: 20226332
[TBL] [Abstract][Full Text] [Related]
7. Correlation between in vitro and in vivo activity of levofloxacin and moxifloxacin against pneumococcal strains with different susceptibilities to fluoroquinolones.
Huelves L; Sevillano D; Martínez-Marín C; López-Casla MT; Gracia M; Alou L; del Carmen Ponte M; Prieto J; Soriano F;
Int J Antimicrob Agents; 2006 Apr; 27(4):294-9. PubMed ID: 16527462
[TBL] [Abstract][Full Text] [Related]
8. Bactericidal activity and target preference of a piperazinyl-cross-linked ciprofloxacin dimer with Staphylococcus aureus and Escherichia coli.
Zhao X; Quinn B; Kerns R; Drlica K
J Antimicrob Chemother; 2006 Dec; 58(6):1283-6. PubMed ID: 17003060
[TBL] [Abstract][Full Text] [Related]
9. Mutational paths towards increased fluoroquinolone resistance in Legionella pneumophila.
Almahmoud I; Kay E; Schneider D; Maurin M
J Antimicrob Chemother; 2009 Aug; 64(2):284-93. PubMed ID: 19474069
[TBL] [Abstract][Full Text] [Related]
10. Mutant-prevention concentrations of enrofloxacin for Escherichia coli isolates from chickens.
Li Q; Bi X; Diao Y; Deng X
Am J Vet Res; 2007 Aug; 68(8):812-5. PubMed ID: 17669019
[TBL] [Abstract][Full Text] [Related]
11. Comparative antibacterial effects of moxifloxacin and levofloxacin on Streptococcus pneumoniae strains with defined mechanisms of resistance: impact of bacterial inoculum.
Bowker KE; Garvey MI; Noel AR; Tomaselli SG; Macgowan AP
J Antimicrob Chemother; 2013 May; 68(5):1130-8. PubMed ID: 23361641
[TBL] [Abstract][Full Text] [Related]
12. Selection of ciprofloxacin resistance in Escherichia coli in an in vitro kinetic model: relation between drug exposure and mutant prevention concentration.
Olofsson SK; Marcusson LL; Komp Lindgren P; Hughes D; Cars O
J Antimicrob Chemother; 2006 Jun; 57(6):1116-21. PubMed ID: 16624874
[TBL] [Abstract][Full Text] [Related]
13. Analysis of the mechanisms of fluoroquinolone resistance in urinary tract pathogens.
Chenia HY; Pillay B; Pillay D
J Antimicrob Chemother; 2006 Dec; 58(6):1274-8. PubMed ID: 17040923
[TBL] [Abstract][Full Text] [Related]
14. Levofloxacin plus metronidazole administered once daily versus moxifloxacin monotherapy against a mixed infection of Escherichia coli and Bacteroides fragilis in an in vitro pharmacodynamic model.
Hermsen ED; Hovde LB; Sprandel KA; Rodvold KA; Rotschafer JC
Antimicrob Agents Chemother; 2005 Feb; 49(2):685-9. PubMed ID: 15673752
[TBL] [Abstract][Full Text] [Related]
15. Low selection of topoisomerase mutants from strains of Escherichia coli harbouring plasmid-borne qnr genes.
Cesaro A; Bettoni RR; Lascols C; Mérens A; Soussy CJ; Cambau E
J Antimicrob Chemother; 2008 May; 61(5):1007-15. PubMed ID: 18325893
[TBL] [Abstract][Full Text] [Related]
16. In vivo activity of gemifloxacin, moxifloxacin and levofloxacin against pneumococci with gyrA and parC point mutations in a sepsis mouse model measured with the all or nothing mortality end-point.
Alkorta M; Giménez MJ; Vicente D; Aguilar L; Pérez-Trallero E
Int J Antimicrob Agents; 2005 Feb; 25(2):163-7. PubMed ID: 15664487
[TBL] [Abstract][Full Text] [Related]
17. Determination of the pharmacodynamic activity of clinically achievable tigecycline serum concentrations against clinical isolates of Escherichia coli with extended-spectrum beta-lactamases, AmpC beta-lactamases and reduced susceptibility to carbapenems using an in vitro model.
Zhanel GG; Baudry PJ; Tailor F; Cox L; Hoban DJ; Karlowsky JA
J Antimicrob Chemother; 2009 Oct; 64(4):824-8. PubMed ID: 19643776
[TBL] [Abstract][Full Text] [Related]
18. Characterization of clinical Escherichia coli isolates from China containing transferable quinolone resistance determinants.
Yang J; Luo Y; Li J; Ma Y; Hu C; Jin S; Ye L; Cui S
J Antimicrob Chemother; 2010 Mar; 65(3):453-9. PubMed ID: 20056688
[TBL] [Abstract][Full Text] [Related]
19. Dose-related selection of fluoroquinolone-resistant Escherichia coli.
Olofsson SK; Marcusson LL; Strömbäck A; Hughes D; Cars O
J Antimicrob Chemother; 2007 Oct; 60(4):795-801. PubMed ID: 17635875
[TBL] [Abstract][Full Text] [Related]
20. Emergence of resistant Streptococcus pneumoniae in an in vitro dynamic model that simulates moxifloxacin concentrations inside and outside the mutant selection window: related changes in susceptibility, resistance frequency and bacterial killing.
Zinner SH; Lubenko IY; Gilbert D; Simmons K; Zhao X; Drlica K; Firsov AA
J Antimicrob Chemother; 2003 Oct; 52(4):616-22. PubMed ID: 12951352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
